Comenzo RL - Search Results

1

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Reece DE, et al. Among authors: comenzo rl. Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8. Blood. 2014. PMID: 25202139 Free PMC article. Clinical Trial.

2

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M. Comenzo RL, et al. Blood. 1996 Oct 1;88(7):2801-6. Blood. 1996. PMID: 8839879 Free article. Clinical Trial.

3

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M. Comenzo RL, et al. Blood. 1998 May 15;91(10):3662-70. Blood. 1998. PMID: 9573002 Free article. Clinical Trial.

4

Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis.

Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S, Berk JL, Dember LM, Falk R, Finn K, Skinner M, Vosburgh E. Comenzo RL, et al. Br J Haematol. 1999 Mar;104(3):553-9. doi: 10.1046/j.1365-2141.1999.01216.x. Br J Haematol. 1999. PMID: 10086794 Free article. Clinical Trial.

5

Hematopoietic cell transplantation for primary systemic amyloidosis: what have we learned.

Comenzo RL. Comenzo RL. Leuk Lymphoma. 2000 Apr;37(3-4):245-58. doi: 10.3109/10428190009089426. Leuk Lymphoma. 2000. PMID: 10752977 Review.

6

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.

Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. Comenzo RL, et al. Blood. 2001 Aug 1;98(3):714-20. doi: 10.1182/blood.v98.3.714. Blood. 2001. PMID: 11468171 Free article.

7

Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis.

Akpek G, Lenz G, Lee SM, Sanchorawala V, Wright DG, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo RL. Akpek G, et al. Among authors: comenzo rl. Bone Marrow Transplant. 2001 Dec;28(12):1105-9. doi: 10.1038/sj.bmt.1703298. Bone Marrow Transplant. 2001. PMID: 11803350

8

Autologous stem cell transplantation for primary systemic amyloidosis.

Comenzo RL, Gertz MA. Comenzo RL, et al. Blood. 2002 Jun 15;99(12):4276-82. doi: 10.1182/blood.v99.12.4276. Blood. 2002. PMID: 12036853 Free article. Review.

9

Primary systemic amyloidosis.

Comenzo RL. Comenzo RL. Curr Treat Options Oncol. 2000 Apr;1(1):83-9. doi: 10.1007/s11864-000-0018-9. Curr Treat Options Oncol. 2000. PMID: 12057064 Review.

10

Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination.

Zhou P, Zhang Y, Martinez C, Kalakonda N, Nimer SD, Comenzo RL. Zhou P, et al. Among authors: comenzo rl. Blood. 2003 Jul 15;102(2):477-9. doi: 10.1182/blood-2002-12-3674. Epub 2003 Mar 20. Blood. 2003. PMID: 12649134 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

193 results

Search Page

Filters